These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37057631)

  • 1. Paradoxical nail psoriasis induced by the IL-17A inhibitor ixekizumab in palmoplantar pustulosis.
    André R; Boehncke WH; Laffitte E
    Int J Dermatol; 2023 Jul; 62(7):e370-e371. PubMed ID: 37057631
    [No Abstract]   [Full Text] [Related]  

  • 2. Local injection of micro-dose guselkumab for palmoplantar pustulosis after partial failure of systemic ixekizumab treatment.
    Zhou C; Chen D; Diao Z; Wang Y; Hou Y; Yin Z
    Australas J Dermatol; 2024 May; 65(3):e75-e76. PubMed ID: 38439213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis.
    Blauvelt A
    Expert Opin Biol Ther; 2016; 16(2):255-63. PubMed ID: 26666707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixekizumab for treatment of psoriasis.
    Dyring-Andersen B; Skov L; Zachariae C
    Expert Rev Clin Immunol; 2015 Apr; 11(4):435-42. PubMed ID: 25748485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.
    Sherman S; Solomon Cohen E; Amitay-Laish I; Hodak E; Pavlovsky L
    Acta Derm Venereol; 2019 Jul; 99(9):769-773. PubMed ID: 31017250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3.
    Dennehy EB; Zhang L; Amato D; Goldblum O; Rich P
    J Drugs Dermatol; 2016 Aug; 15(8):958-61. PubMed ID: 27537996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixekizumab for the treatment of psoriasis: an update on new data since first approval.
    Blegvad C; Skov L; Zachariae C
    Expert Rev Clin Immunol; 2019 Feb; 15(2):111-121. PubMed ID: 30589394
    [No Abstract]   [Full Text] [Related]  

  • 8. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
    van Vugt LJ; van den Reek JMPA; Meulewaeter E; Hakobjan M; Heddes N; Traks T; Kingo K; Galluzzo M; Talamonti M; Lambert J; Coenen MJH; de Jong EMGJ
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):112-118. PubMed ID: 31287604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting IL-17 with ixekizumab in patients with psoriasis.
    Dyring-Andersen B; Skov L; Zachariae C
    Immunotherapy; 2015; 7(9):957-66. PubMed ID: 26569072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3.
    Egeberg A; Kristensen LE; Vender R; Zaheri S; El Baou C; Gallo G; Riedl E; Schuster C
    Acta Derm Venereol; 2022 Oct; 102():adv00787. PubMed ID: 36121210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients.
    Cao H; Su S; Yang Q; Le Y; Chen L; Hu M; Guo X; Zheng J; Li X; Yu Y
    Lipids Health Dis; 2021 Feb; 20(1):16. PubMed ID: 33602246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
    Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
    Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
    Bokor-Billmann T; Schäkel K
    J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ixekizumab (Taltz)--a second IL-17A inhibitor for psoriasis.
    Med Lett Drugs Ther; 2016 May; 58(1494):59-60. PubMed ID: 27148922
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-interleukin-17 treatment of psoriasis.
    Jinna S; Strober B
    J Dermatolog Treat; 2016 Aug; 27(4):311-5. PubMed ID: 26943806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ixekizumab: First Global Approval.
    Markham A
    Drugs; 2016 May; 76(8):901-5. PubMed ID: 27098317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis.
    Peranteau AJ; Turkeltaub AE; Tong Y; Nawas Z; Tyring SK
    Skin Therapy Lett; 2016 Nov; 21(6):1-6. PubMed ID: 27825174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-17 inhibitors for psoriasis.
    Paek SY; Frieder J; Kivelevitch D; Menter MA
    Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F.
    Adams R; Maroof A; Baker T; Lawson ADG; Oliver R; Paveley R; Rapecki S; Shaw S; Vajjah P; West S; Griffiths M
    Front Immunol; 2020; 11():1894. PubMed ID: 32973785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.